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Antifungal
In earlier rat VVC studies, topical CD101 gel given BID eradicated azole-susceptible C. albicans (ATCC 44858) up to at least 1 week after treatment cessation 2 . Fluconazole given orally showed modest improvement whereas topical miconazole (2% cream) showed fungal rebound less than 1 week after treatment cessation. Highly stable echinocandin CD101 is a novel echinocandin being developed for the treatment of fungal infections. Echinocandins have been successfully and safely used as intravenous antifungal therapy for 15 years. Like previously approved echinocandins, CD101 is fungicidal against Candida spp. Unlike previously approved echinocandins, CD101 has a uniquely stabilized structure enabling it to be formulated for topical administration and developed for treatment of VVC.
CD101 was designed to be a highly stable molecule and has shown robust efficacy in mouse infection models of disseminated Candida/Aspergillus. CD101 has an excellent nonclinical safety and toxicology profile enabling high concentration, front-loaded doses, and is currently in Phase 2 clinical trials for candidemia and vulvovaginal candidiasis (VVC).
Topical formulations of CD101 were optimized and found to be efficacious using a rat VVC model. Initial rat VVC studies were performed using an azole-susceptible C. albicans strain (ATCC 44858). We have subsequently developed mouse disseminated and rat VVC infection models using an azole-resistant C. albicans strain (R357). The results of these studies are presented and discussed in this poster. With optimization, a slower release gel formulation of CD101 was developed that enabled once daily (QD) topical administration. This slower release CD101 gel formulation was found to be highly effective in the rat VVC model of azole-resistant C. albicans (R357). The vaginal lavage CFU showed that topical CD101 cleared the vaginal infection and reduced fungal burden for at least 1 week after treatment cessation. Nystatin (2.3% or 100,000 USP/g), a polyene antifungal, did not appear to reduce vaginal CFU as effectively on day 5 compared to CD101. Reduction in vaginal lavage CFU suggested CD101 was fungicidal (> 3-log reduction) against C. albicans.
Mouse disseminated infection model
CD101 also showed comparable cidality in vaginal tissue CFU reduction. 
